Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 6—June 2018

Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission

Maxime HentzienComments to Author , Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, Moustapha Dramé, Firouzé Bani-Sadr, Jean-Marc Galempoix, Christophe Strady, Jean-Marc Reynes, Christian Penalba, and Amélie Servettaz
Author affiliations: University of Reims Champagne-Ardenne, Reims, France (M. Hentzien, M. Dramé); Hôpital Universitaire Robert Debré, Reims (M. Hentzien, M. Dramé, F. Bani-Sadr, A. Servettaz); Manchester Hospital, Charleville-Mézières, France (S. Mestrallet, P. Halin, L.-A. Pannet, D. Lebrun, J.-M. Galempoix, C. Penalba); Groupe Courlancy, Reims (C. Strady); Institut Pasteur, Lyon, France (J.-M. Reynes)

Main Article

Table 3

Point value assigned for each predictive factor of severe nephropathia epidemica to be used for bioclinical assay to access risk for nephropathia epidemica severity*

Predictive factor Point value
Hematuria 7
Visual disorders 8
Leukocyte count >10 × 109 cells/L 9
Nephrotoxic drug exposure† 10
Thrombocytopenia <90 × 109/L 11

*Predictive factors were assessed at admission.
†Nephrotoxic drugs included nonsteroidal antiinflammatory drugs, iodinated contrast media, diuretics, renin angiotensin aldosterone system inhibitors, and nephrotoxic antimicrobial drugs (aminoglycosides, glycopeptides).

Main Article

Page created: May 15, 2018
Page updated: May 15, 2018
Page reviewed: May 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.